Cardiac safety of diabetes therapies and postmarketing requirements.

Pharmacoepidemiol Drug Saf

United BioSource Corporation, Blue Bell, PA, 19422 USA.

Published: August 2008

Download full-text PDF

Source
http://dx.doi.org/10.1002/pds.1622DOI Listing

Publication Analysis

Top Keywords

cardiac safety
4
safety diabetes
4
diabetes therapies
4
therapies postmarketing
4
postmarketing requirements
4
cardiac
1
diabetes
1
therapies
1
postmarketing
1
requirements
1

Similar Publications

Comparative Effectiveness of Individual Sodium-Glucose Cotransporter 2 Inhibitors.

JAMA Intern Med

January 2025

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Importance: Evidence on cardiovascular benefits and safety of sodium-glucose cotransporter 2 (SGLT-2) inhibitors is mainly from placebo-controlled trials. Therefore, the comparative effectiveness and safety of individual SGLT-2 inhibitors remain unknown.

Objective: To compare the use of canagliflozin or dapagliflozin with empagliflozin for a composite outcome (myocardial infarction [MI] or stroke), heart failure hospitalization, MI, stroke, all-cause death, and safety outcomes, including diabetic ketoacidosis (DKA), lower-limb amputation, bone fracture, severe urinary tract infection (UTI), and genital infection and whether effects differed by dosage or cardiovascular disease (CVD) history.

View Article and Find Full Text PDF

Cardiovascular imaging in children with cardiac implantable electronic devices.

Pediatr Radiol

January 2025

Department of Cardiology, Boston Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA, 02115, USA.

The number of children with cardiac implantable electronic devices (CIEDs) is increasing at a time of rapid growth in cardiac magnetic resonance (MR) and cardiac computed tomography (CT) utilization. The presence of CIEDs poses challenges with respect to imaging safety and quality. A thoughtful approach to cardiovascular imaging in patients with CIEDs begins with an awareness of the clinical indications to determine the most appropriate imaging modality.

View Article and Find Full Text PDF

Prussian Blue Nanozyme Featuring Enhanced Superoxide Dismutase-like Activity for Myocardial Ischemia Reperfusion Injury Treatment.

ACS Nano

January 2025

Jiangsu Key Laboratory for Biomaterials and Devices, School of Biomedical Sciences and Medical Engineering, Southeast University, Nanjing 210096, P. R. China.

The blood flow, when restored clinically following a myocardial infarction (MI), disrupts the physiological and metabolic equilibrium of the ischemic myocardial area, resulting in secondary damage termed myocardial ischemia-reperfusion injury (MIRI). Reactive oxygen species (ROS) generation and inflammatory reactions stand as primary culprits behind MIRI. Current strategies focusing on ROS-scavenging and anti-inflammatory actions have limited remission of MIRI.

View Article and Find Full Text PDF

Background: GLP-1 RAs improve cardiometabolic outcomes in obese, diabetic, and heart failure patients. Data on the safety and efficacy of GLP-1 RA in advanced heart failure with durable LVAD is limited.

Objectives: To assess the safety and efficacy of GLP-1 RA in durable LVAD patients.

View Article and Find Full Text PDF

The performing of non-physician led exercise stress testing with and without echocardiography has shown similar diagnostic utility and safety as physician led models. While diagnostic accuracy and relative safety have been the focus of previous research, the current study aims to demonstrate efficiencies not previously reported such as reduction in wait times for testing and improved service attendance. A non-physician led exercise stress echocardiography (ESE) service was implemented on 01/01/2018, prior to this all tests were performed under a physician led model.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!